CN106957826A - A kind of virus inactivator and its application - Google Patents
A kind of virus inactivator and its application Download PDFInfo
- Publication number
- CN106957826A CN106957826A CN201710148704.7A CN201710148704A CN106957826A CN 106957826 A CN106957826 A CN 106957826A CN 201710148704 A CN201710148704 A CN 201710148704A CN 106957826 A CN106957826 A CN 106957826A
- Authority
- CN
- China
- Prior art keywords
- virus
- extract
- inactivator
- virus inactivator
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 92
- 230000000937 inactivator Effects 0.000 title claims abstract description 44
- 239000000284 extract Substances 0.000 claims abstract description 45
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 23
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 23
- 235000021511 Cinnamomum cassia Nutrition 0.000 claims abstract description 22
- 230000002779 inactivation Effects 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 8
- 241001430294 unidentified retrovirus Species 0.000 claims abstract description 8
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 6
- 241000175212 Herpesvirales Species 0.000 claims abstract description 5
- 241000522254 Cassia Species 0.000 claims description 26
- 239000000463 material Substances 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 18
- 238000000605 extraction Methods 0.000 claims description 14
- 239000013049 sediment Substances 0.000 claims description 14
- 239000012141 concentrate Substances 0.000 claims description 12
- 238000012805 post-processing Methods 0.000 claims description 12
- 238000002203 pretreatment Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 11
- 102000036639 antigens Human genes 0.000 claims description 11
- 108091007433 antigens Proteins 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 11
- 235000017803 cinnamon Nutrition 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 241000723347 Cinnamomum Species 0.000 claims description 7
- 235000015097 nutrients Nutrition 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 229940031551 inactivated vaccine Drugs 0.000 claims description 6
- 239000008363 phosphate buffer Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 238000007873 sieving Methods 0.000 claims description 6
- 230000003612 virological effect Effects 0.000 claims description 5
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 229940124873 Influenza virus vaccine Drugs 0.000 claims description 3
- 239000006286 aqueous extract Substances 0.000 claims description 2
- 230000010261 cell growth Effects 0.000 claims description 2
- 230000009514 concussion Effects 0.000 claims description 2
- 239000002054 inoculum Substances 0.000 claims description 2
- 208000002352 blister Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 7
- 101710091045 Envelope protein Proteins 0.000 abstract description 2
- 101710188315 Protein X Proteins 0.000 abstract description 2
- 102100021696 Syncytin-1 Human genes 0.000 abstract description 2
- 230000003321 amplification Effects 0.000 abstract description 2
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 2
- 238000011160 research Methods 0.000 abstract description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 32
- 239000000243 solution Substances 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000002574 poison Substances 0.000 description 12
- 231100000614 poison Toxicity 0.000 description 12
- 230000000840 anti-viral effect Effects 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 235000019082 Osmanthus Nutrition 0.000 description 8
- 241000333181 Osmanthus Species 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 230000023555 blood coagulation Effects 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 244000080208 Canella winterana Species 0.000 description 5
- 235000008499 Canella winterana Nutrition 0.000 description 5
- 229940017545 cinnamon bark Drugs 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000003501 vero cell Anatomy 0.000 description 4
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 3
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 101710132601 Capsid protein Proteins 0.000 description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 2
- 101710094648 Coat protein Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 101710083689 Probable capsid protein Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 102000016912 Aldehyde Reductase Human genes 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- 241001327915 Cinnamomum mairei Species 0.000 description 1
- 206010069767 H1N1 influenza Diseases 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002391 anti-complement effect Effects 0.000 description 1
- -1 anti-inflammatory Proteins 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 108010008730 anticomplement Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16061—Methods of inactivation or attenuation
- C12N2710/16063—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10061—Methods of inactivation or attenuation
- C12N2740/10063—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16161—Methods of inactivation or attenuation
- C12N2760/16163—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16261—Methods of inactivation or attenuation
- C12N2760/16263—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16311—Influenzavirus C, i.e. influenza C virus
- C12N2760/16361—Methods of inactivation or attenuation
- C12N2760/16363—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18061—Methods of inactivation or attenuation
- C12N2760/18063—Methods of inactivation or attenuation by chemical treatment
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of virus inactivator and its application.Described virus inactivator is 0.5 ~ 1mg/ml of final concentration cinnamomum cassia extract.Using the application for described virus inactivator in inactivation paramyxovirus, herpesviral, retrovirus and influenza virus medicine is prepared.The invention discloses a kind of cinnamomum cassia extract（KPC‑rg1）Inactivation of virus effect, research has shown that, this kind of extract can occur at normal temperatures with the envelope protein of virus coat it is rapid, strongly be combined so that inactivation of virus, losing infection and amplification ability, but possess antigenicity.
Description
Technical field
The invention belongs to pharmaceutical technology field, and in particular to a kind of virus inactivator and its application.
Background technology
The main vaccine of current domestic and international application includes attenuated vaccine and inactivated vaccine.Due to the production technology of inactivated vaccine
Simply, it is safe, easy to use, be easy to preserve, can stimulating animal produce high titre antibody and significant vaccine protecting effect etc. it is excellent
Point, therefore the high-quality and efficient inactivated vaccine of exploitation is the most effective means of the various virus infections of prevention and control.Inactivated vaccine, turns round and look at name
Think justice to seek to the pathogen with infective work with appropriate either physically or chemically inactivation, make its forfeiture pathogenic,
But still retain its immunogenicity, the vaccine manufactured with it.
Traditional virus inactivator formaldehyde, is a kind of carcinogen for having an intense irritation.It both may act on virus and had contained
The nucleotide base of amino, may act on virus coat protein again.When formaldehyde acts on virus coat protein, easily hand over protein
Connection or virion aggregation, so that the neutralization immunogenicity of pathogen protein is seriously damaged.And use the formalin-inactivated time
It is long, generally require and more than 24h or longer time are handled at 37~39 DEG C；The free formaldehyde of residual, if with vaccine implanter
After body, irritative response can be produced.Therefore, on the premise of ensureing that inactivation is perfectly safe, when improving inactivation speed, shortening inactivation
Between, the loss of Effective Antigens is reduced, is always the development goal of new virus inactivator.
Chinese cassia tree is China's parts of generic medicinal plants, first recorded in《Sheng Nong's herbal classic》, top grade is classified as, the successive dynasties, important book on Chinese herbal medicine had note
Carry.Chinese cassia tree and its contained composition have many pharmacological actions, common reporter include antibacterial, it is anti-oxidant, hypoglycemic, anti-
Aldose reductase, anti-inflammatory, anticomplement, antitumor activity, and to digestive system, cardiovascular system, immune system, maincenter god
Adjustment effect through, internal system.The report that Chinese cassia tree is used to prevent and treat virus infection is few.
The content of the invention
The first object of the present invention is to provide a kind of virus inactivator；Second purpose is the inactivation of virus described in offer
The application of agent.
The first object of the present invention is achieved in that the Chinese cassia tree that described virus inactivator is 0.5 ~ 1mg/ml of final concentration
Extract.
The second object of the present invention is achieved in that described virus inactivator is preparing inactivation paramyxovirus, blister
Application in exanthema virus, retrovirus and influenza virus medicine.
The invention discloses a kind of cinnamomum cassia extract（KPC-rg1）Inactivation of virus effect, research has shown that, this kind extract
Thing can occur at normal temperatures with the envelope protein of virus coat it is rapid, strongly be combined, so that inactivation of virus, losing infection
And amplification ability, but possess antigenicity.
Chinese cassia tree of the present invention includes：Chinese cassia tree, great Ye Qinghua osmanthus, Ceylon cinnamon, south China osmanthus, cinnamomum obtusifoliumNees, burmannii, India
Osmanthus, Cinnamomum mairei Levl., fragrant osmanthus, bavin osmanthus, river osmanthus；It is preferred that, the Chinese cassia tree includes：Chinese cassia tree, great Ye Qinghua osmanthus and Ceylon cinnamon；More preferably
, the Chinese cassia tree includes：Chinese cassia tree and great Ye Qinghua osmanthus.
The plant parts of the Chinese cassia tree are bark.
The method of inactivator inactivation of viruses of the present invention is by virus liquid to be inactivated virus of the present invention
Inactivator carries out 4 ~ 37 DEG C of inactivation.
Brief description of the drawings
Fig. 1 is virus inactivator cinnamomum cassia extract of the present invention（KPC-rg1）The inhibitory action signal bred to vero cells
Figure；
Influence schematic diagram after the HSV-1 virus infected cells that Fig. 2 pre-processes for HSV-1 and KPC-rg1 to cellular morphology；
Fig. 3 is HSV-1 virus titer change schematic diagrams after KPC-rg1 is handled；
Fig. 4 attacks the situation of change schematic diagram of Mouse Weight after poison for H1N1；
Fig. 5 is the blood clotting suppression potency schematic diagram in mice serum for H1N1 viruses；
Fig. 6 is the 3rd day and experimental endpoints after infection（28 days）Each group mouse lung H1N1 virus M gene RNA copy number schematic diagrames.
Embodiment
With reference to embodiment and accompanying drawing, the present invention is further illustrated, but the present invention is not subject in any way
Limitation, based on present invention teach that any conversion or replacement made, belong to protection scope of the present invention.
Virus inactivator of the present invention is 0.5 ~ 1mg/ml of final concentration cinnamomum cassia extract.
Described virus inactivator also includes the cinnaldehydrum of cinnamomum cassia extract percentage by weight 1 ~ 5%；
Described cinnamomum cassia extract is the Chinese cassia tree Aqueous extracts prepared under conditions of pH value is 1 ~ 5.
Described cinnamomum cassia extract is to be prepared by raw material of Chinese cassia tree through pre-treatment, extraction, post-processing step, specific bag
Include following steps：
A, pre-treatment：The material a of the broken sieving of raw material ground cinnamon is standby；
B, extraction：The water of 3 ~ 30 times of material a weight is added in material a, in extracting 1 ~ 3 time at 4 ~ 80 DEG C of temperature, 1 ~ 24h every time,
Merge extract solution and obtain extract solution b；
C, post processing：Extract solution b is concentrated into relative density to obtain adding acidity in concentrate c, concentrate c for 1.01 ~ 1.05
In phosphate buffer, with salt acid for adjusting pH value to 1 ~ 5,8 ~ 24h is stood, it is described cinnamomum cassia extract to take sediment fraction；
Add the well mixed as object virus inactivator of cinnaldehydrum of sediment fraction percentage by weight 1 ~ 5%.
Described cinnamomum cassia extract is to be prepared by raw material of Chinese cassia tree through pre-treatment, extraction, post-processing step, specific bag
Include following steps：
A, pre-treatment：The material a of the broken sieving of raw material ground cinnamon is standby；
B, extraction：The water of 3 ~ 12 times of material a weight is added in material a, is extracted 1 ~ 3 time at 4 ~ 40 DEG C of temperature, 1 ~ 8h, is closed every time
And extract solution obtains extract solution b；
C, post processing：Extract solution b is concentrated into relative density to obtain adding pH value 3 in concentrate c, concentrate c for 1.01 ~ 1.05
In ~ 6 acidic phosphate buffer, with salt acid for adjusting pH value to 2 ~ 4,8 ~ 24h is stood, it is described Chinese cassia tree to take sediment fraction
Extract；Add the well mixed as object virus inactivator of cinnaldehydrum of sediment fraction percentage by weight 1 ~ 5%.
Described cinnamomum cassia extract is to be prepared by raw material of Chinese cassia tree through pre-treatment, extraction, post-processing step, specific bag
Include following steps：
A, pre-treatment：The material a of the broken sieving of raw material ground cinnamon is standby；
B, extraction：The water of 10 times of material a weight is added in material a, is extracted 3 times at 20 DEG C of temperature, each 2h merges extract solution
Obtain extract solution b；
C, post processing：Extract solution b is concentrated into relative density to obtain adding pH value 6 in concentrate c, concentrate c for 1.01 ~ 1.05
Acidic phosphate buffer in, with salt acid for adjusting pH value to 3, stand 12h, it is that described Chinese cassia tree is extracted to take sediment fraction
Thing；Add the well mixed as object virus inactivator of cinnaldehydrum of sediment fraction percentage by weight 1 ~ 5%.
The application of virus inactivator of the present invention is that described virus inactivator is preparing inactivation paramyxovirus, blister
Application in exanthema virus, retrovirus and influenza virus medicine.
Described virus inactivator is preparing inactivation paramyxovirus, herpesviral, retrovirus and influenza virus
Application in vaccine.
The described preparation method bag for inactivating paramyxovirus, herpesviral, retrovirus and influenza virus vaccine
Include following steps：
A, prepare antigen liquid；
After B, the cinnamomum cassia extract that addition concentration is 0.5 ~ 1mg/ml in antigen liquid are fully mixed, mixed liquor is positioned over temperature
5 ~ 10min, which is incubated, for concussion under conditions of 20 ~ 30 DEG C obtains object inactivated vaccine；Wherein cinnamomum cassia extract and antigen liquid is matched somebody with somebody
It is 1 than ratio：2.5（Wherein cinnamomum cassia extract is in terms of mass unit, and virus is in terms of blood coagulation unit）.
The described antigen liquid for preparing is to be seeded in virus in host cell by the inoculum concentration of percentage by volume 1% ~ 3%, when
When host cell growth is to 40% ~ 90%, nutrient solution is replaced by maintaining liquid, maintains collection virus after 48 ~ 72h of observation to obtain antigen
Liquid.
Described nutrient solution is that described nutrient solution is according to the different corresponding selections of virus host cells（Virus host cells
Difference, culture medium is also different）；Described maintaining liquid is the nutrient solution containing 2% hyclone.
So that case is embodied, the present invention will be further described below：
The preparation of the virus inactivator of embodiment 1
Step one：Cinnamon bark is crushed, with 3 times of amount 4 DEG C of water soak extractions 1 time, extracted 1 hour.Step 2：Filtration, takes filter
Liquid, the dregs of a decoction are standby.Step 3：Filtrate adds ethanol to ethanol content up to 65%, stands.Step 4: centrifugation, supernatant is standby simultaneously
Preserve precipitation.Step 5：The supernatant in step 4 is taken, is concentrated under reduced pressure, is dried in vacuo.Step 6：It is dissolved in water, filters.Step
Rapid seven：Filtrate adjusts pH value to 5 with watery hydrochloric acid.Step 8：Filtering, takes precipitation, dries.By step 4 and step 8 and commercially available cassia bark
Aldehyde presses 10:10:0.5 ratio mixing both the virus inactivator.
The preparation of the virus inactivator of embodiment 2
Step one：Cinnamon bark is crushed, with 8 times of amount water normal temperature（20 ℃）Stirring 3 times, every time two hours.Step 2：Filtration,
Filtrate is taken, the dregs of a decoction are standby.Step 3：Filtrate adds ethanol to ethanol content up to 80%, stands.Step 4: centrifugation, supernatant is standby
With reservation sediment fraction.Step 5：By the supernatant in step 4, it is concentrated under reduced pressure, is dried in vacuo.Step 6：It is dissolved in water,
Filtering.Step 7：Filtrate adjusts pH value to 2 with watery hydrochloric acid.Step 8：Filtering, takes precipitation, dries.By step 4 and step 8 and
Commercially available cinnaldehydrum presses 10:10:0.5 ratio mixing both the virus inactivator.
The cinnamon bark total starches of embodiment 3, the preparation of total polyphenols
The preparation of cinnamon bark total starches：Step one：Cinnamon bark is crushed, extraction 3 times is stirred with 30 times of 80 DEG C of amount water, often
Secondary 24 hours.Step 2：Filtration, takes filtrate, the dregs of a decoction are standby.Step 3：Filtrate adds ethanol to ethanol content up to 90%, stands.
Step 4: centrifugation, supernatant is standby, retain sediment fraction.Step 5：By the supernatant in step 4, it is concentrated under reduced pressure, vacuum is done
It is dry.Step 6：It is dissolved in water, filters.Step 7：Filtrate adjusts pH value to 1 with watery hydrochloric acid.Step 8：Filtering, takes precipitation, dries.
Step 4 and step 8 and commercially available cinnaldehydrum are pressed 10:10:0.5 ratio mixing both the virus inactivator.
Embodiment 6
The inhibitory action that KPC-rg1 breeds to vero cells
The orifice plate of vero plating cells 96, in 37 DEG C, 5% C02Incubator, which is stayed overnight, to be covered with after individual layer, and the Chinese cassia tree for adding various concentrations carries
Take thing（kpc-rg1）, set each with the detection of CCK8 kits after experimental group, cell controls group, blank control group, 48h respectively
OD values under concentration, cell survival rate is calculated according to formula.As a result show, when kpc-rg1 concentration is less than 0.05mg/ml,
Vero cells acellular poison is acted on.Specific data are shown in Fig. 1.
Embodiment 7
Suppression of the KPC-rg1 to HSV-1 virus activities
40ug/ml KPC-rg1 and Mol=0.1 HSV-1 virus liquids are incubated 24 hours jointly at 4 degree, vero is then added to
In 96 orifice plates of plating cells, while setting virus control and cell controls (being not added with virus, only add culture medium), culture 24 is small
When after observation of cell form under microscope, and calculate the TCID50 values of viral suspension.As a result show, KPC-rg1 is to HSV-1 diseases
The deactivation of poison significantly, and plays a very good protection to vero cells.Specific experiment result is shown in Fig. 2, Fig. 3.
Embodiment 8
KPC-rg1 is tested the Anti-viral activity in vitro of RSV viruses and HIV-1 viruses
Sample preparation：KPC-rg1 is dissolved with sterile water-soluble heated to 8 mg/ml and in 80 DEG C of water-baths 15 minutes.Solution in
2000 RPM take supernatant to be stored in 4 DEG C as KPC-rg1 mother liquors after centrifuging 2 minutes.In EC50 determination experiments, KPC-rg1 and
Reference compound tests 8 concentration points, each concentration determination duplicate hole by 3 times of doubling dilutions.Highest test concentrations are 1000 μ
g/ml.DMSO ultimate densities in cell culture medium are 0.5%.And the method for according to the form below carries out antiviral activity test：
The Antiviral breeding method list of table 1
RSV Along pathological changes caused by virus is tested：Cell is with certain density（Table 1）It is inoculated into microwell plate and in 37 DEG C, 5%
Overnight incubation in CO2 incubators.Second day, the compound and virus of various concentrations（Table 1）Premixed liquid add cell plates in
37 DEG C, it is complete that 5% CO2 cultivates the 3-5 days cytopathies into virus control wells.Cytoactive then uses CCK8 cell viabilities
Detection kit is detected according to the explanation of detection reagent.Antiviral activity under compound various concentrations to virus by causing
The inhibitory action of cytopathic effect determine.All data are through blank infection control calibration.EC50 is by GraphPad
Prism softwares carry out analysis calculating.
HIV-1 pathological changes caused by virus is tested：With virus after test compound and reference compound doubling dilution（Table 1）It is mixed
Close, mixed liquor and the MT-4 cells of subsequent compound and virus add microwell plate and in 33 DEG C or 37 DEG C, 5% CO2 incubators
Cultivate the 2-6 days cytopathies into virus control wells complete.Cytoactive then uses CCK8 or CellTiter Glo cells
Viability detection kit is detected according to the explanation of detection reagent.Antiviral activity of the compound under various concentrations is by disease
The inhibitory action of cytopathic effect caused by malicious is determined.EC50 carries out analysis calculating by GraphPad Prism softwares.
As a result show, the antiviral activity of the reference compound of all antiviral activity experiments of this experiment meets with expection,
Prove that this experimental result is reliable.KPC-rg1 antiviral activity is similar with positive control drug, has preferable activity to two kinds of viruses
Inhibitory action, the results are shown in Table 2.
The cinnamomum cassia extract antiviral activity list of table 2.
Embodiment 9
Checking KPC-rg1 resisiting influenza virus is acted on and produced due to " in-situ solidifying immunological effect " that KPC-rg1 is induced
Animal protection effect
Experiment material and animal packet
Test sample：KPC-rg1
Experimental virus strain：H1N1 (A/Puerto Rico/8/1934).Virus is bred by MDCK.Strain-
Its HA titer is measured before 70 DEG C of storages（HAU）For 256；Experiment is 250HAU with virus.
Experimental animal and packet：The mouse at 28-30 days ages.
A) PBS control group：6 mouse.
B) viral group（PR8 attacks malicious group）：8 mouse（250 HAU/ are only）.
C）KPC-rg1 administration groups, totally 8 mouse.
Experimental method
The KPC-rg1 of prescribed dose（100ug/only）With virus（250 HAU/ are only）At room temperature training is pre-mixed with appropriate PBS
Support 5-10 min.KPC-rg1/ viral solutions or viral solution that the mouse inoculation at 28-30 days ages has been pre-mixed.KPC-
Cumulative volume of the rg1/ viruses in PBS is 50 ul/ mouse.Anaesthetized before inoculation.PBS is as blank control.Observe mouse 28 days
Survival level.And in experimental endpoints（28 days）Mice serum is collected in eyeball blood sampling, carries out erythrocyte agglutination Inhibition test（HI）Inspection
Survey in mice serum and suppress potency for the blood clotting of H1N1 viruses（HI titer）.It is positive effectively HI that blood clotting, which suppresses Jie Guo≤20,
Potency.n=3.Simultaneously in the 3rd day after infection and experimental endpoints（28 days）Mouse lung is obtained, lung total serum IgE, RT-PCR detection each groups is extracted
Mouse lung H1N1 virus M gene RNA copy numbers.
Experimental result
28 days survival conditions of mouse
Table 3 each group mouse, 28 days survival levels
Attack poison group mouse and death occur within the 3rd day after poison is attacked, attack dead more than half in malicious one week after, survival rate is 37.5%（It is 8 small
Mouse amounts to dead 5）.KPC-rg1 groups do not occur death after poison is attacked, and survival rate is absolutely.Body weight and existence result are disclosed
Medicine has notable protectiveness effect to mouse.
Mouse Weight situation of change is shown in Fig. 4
Compare PBS group Mouse Weight steady growths, and be related to virus attack attack malicious group, KPC-rg1 groups Mouse Weight attacking
Decline after poison, body weight is gradually recovered and risen after one week.
Mouse blood clotting suppresses potency（Antibody level）See Fig. 5
28 days after infection, malicious group attacked, can detect that 128 blood clotting suppresses potency in KPC-rg1 group mice serums, show virus
Attack to mouse makes mouse immune system generate corresponding antibodies and protectiveness.
Fig. 6 is shown in the detection of mouse lung virus load
3 days detection virus infection pulmonary conditions after poison are attacked, each group mouse lung virus load reaches 10 every 50 mg of 7 powers
Lung, shows virus in mouse lung infection development situation.During experimental endpoints 28 days, attack poison group mouse lung virus load and detected
Less than, show virus removed by mouse immune system.The above results disclose virus from infection again to the pulmonary infection of removing
Process.
Summary result, virus is infected each group mouse lung after poison is attacked, and is caused to attack poison group mouse and is existed
Infect dead more than half in one week after.And KPC-rg1 groups mouse does not occur the phenomena of mortality, show medicine to H1N1 influenza viruse attacks
Mouse has notable protecting effect.Attack the poison group and medicine group mouse survived for 28 days after infection has significant antibody to produce,
Virus has also been removed by body immune system.
Claims (10)
1. a kind of virus inactivator, it is characterised in that described virus inactivator is extracted for 0.5 ~ 1mg/ml of final concentration Chinese cassia tree
Thing.
2. virus inactivator according to claim 1, it is characterised in that described virus inactivator also includes Chinese cassia tree and extracted
The cinnaldehydrum of thing percentage by weight 1 ~ 5%；Described cinnamomum cassia extract is the Chinese cassia tree prepared under conditions of pH value is 1 ~ 5
Aqueous extracts.
3. virus inactivator according to claim 1 or 2, it is characterised in that described cinnamomum cassia extract is using Chinese cassia tree as original
Material is prepared through pre-treatment, extraction, post-processing step, specifically includes following steps：
A, pre-treatment：The material a of the broken sieving of raw material ground cinnamon is standby；
B, extraction：The water of 3 ~ 30 times of material a weight is added in material a, in extracting 1 ~ 3 time at 4 ~ 80 DEG C of temperature, 1 ~ 24h every time,
Merge extract solution and obtain extract solution b；
C, post processing：Extract solution b is concentrated into relative density to obtain adding acidity in concentrate c, concentrate c for 1.01 ~ 1.05
In phosphate buffer, with salt acid for adjusting pH value to 1 ~ 5,8 ~ 24h is stood, it is described cinnamomum cassia extract to take sediment fraction；
Add the well mixed as object virus inactivator of cinnaldehydrum of sediment fraction percentage by weight 1 ~ 5%.
4. virus inactivator according to claim 3, it is characterised in that described cinnamomum cassia extract is using Chinese cassia tree as raw material
Prepared through pre-treatment, extraction, post-processing step, specifically include following steps：
A, pre-treatment：The material a of the broken sieving of raw material ground cinnamon is standby；
B, extraction：The water of 3 ~ 12 times of material a weight is added in material a, is extracted 1 ~ 3 time at 4 ~ 40 DEG C of temperature, 1 ~ 8h, is closed every time
And extract solution obtains extract solution b；
C, post processing：Extract solution b is concentrated into relative density to obtain adding pH value 3 in concentrate c, concentrate c for 1.01 ~ 1.05
In ~ 6 acidic phosphate buffer, with salt acid for adjusting pH value to 2 ~ 4,8 ~ 24h is stood, it is described Chinese cassia tree to take sediment fraction
Extract；Add the well mixed as object virus inactivator of cinnaldehydrum of sediment fraction percentage by weight 1 ~ 5%.
5. virus inactivator according to claim 3, it is characterised in that described cinnamomum cassia extract is using Chinese cassia tree as raw material
Prepared through pre-treatment, extraction, post-processing step, specifically include following steps：
A, pre-treatment：The material a of the broken sieving of raw material ground cinnamon is standby；
B, extraction：The water of 10 times of material a weight is added in material a, is extracted 3 times at 20 DEG C of temperature, each 2h merges extract solution
Obtain extract solution b；
C, post processing：Extract solution b is concentrated into relative density to obtain adding pH value 6 in concentrate c, concentrate c for 1.01 ~ 1.05
Acidic phosphate buffer in, with salt acid for adjusting pH value to 3, stand 12h, it is that described Chinese cassia tree is extracted to take sediment fraction
Thing；Add the well mixed as object virus inactivator of cinnaldehydrum of sediment fraction percentage by weight 1 ~ 5%.
6. the application of any described virus inactivator of a kind of claim 1 ~ 5, it is characterised in that described virus inactivator exists
Prepare the application in inactivation paramyxovirus, herpesviral, retrovirus and influenza virus medicine.
7. the application of virus inactivator according to claim 6, it is characterised in that described virus inactivator is gone out in preparation
Application in paramyxovirus living, herpesviral, retrovirus and influenza virus vaccine.
8. the application of virus inactivator according to claim 7, it is characterised in that described inactivation paramyxovirus, bleb
The preparation method of virus, retrovirus and influenza virus vaccine comprises the following steps：
A, prepare antigen liquid；
After B, the cinnamomum cassia extract that addition concentration is 0.5 ~ 1mg/ml in antigen liquid are fully mixed, mixed liquor is positioned over temperature
5 ~ 10min, which is incubated, for concussion under conditions of 20 ~ 30 DEG C obtains object inactivated vaccine；Wherein cinnamomum cassia extract and antigen liquid is matched somebody with somebody
It is 1 than ratio：2.5.
9. the application of virus inactivator according to claim 8, it is characterised in that the described antigen liquid for preparing is by virus
It is seeded in by the inoculum concentration of percentage by volume 1% ~ 3% in host cell, when host cell growth is to 40% ~ 90%, by nutrient solution
Maintaining liquid is replaced by, maintains collection virus after 48 ~ 72h of observation to obtain antigen liquid.
10. the application of virus inactivator according to claim 9, it is characterised in that described nutrient solution is according to viral place
Chief cell difference corresponding selection；Described maintaining liquid is the nutrient solution containing 2% hyclone.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710148704.7A CN106957826B (en) | 2017-03-14 | 2017-03-14 | Virus inactivating agent and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710148704.7A CN106957826B (en) | 2017-03-14 | 2017-03-14 | Virus inactivating agent and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106957826A true CN106957826A (en) | 2017-07-18 |
| CN106957826B CN106957826B (en) | 2020-02-07 |
Family
ID=59470645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710148704.7A Active CN106957826B (en) | 2017-03-14 | 2017-03-14 | Virus inactivating agent and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106957826B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112294868A (en) * | 2019-07-31 | 2021-02-02 | 昆明扬添生物科技有限公司 | Medicine for virus inactivation, sanitation disinfection and generation of immunity activation |
| CN118593562A (en) * | 2024-05-21 | 2024-09-06 | 西北农林科技大学深圳研究院 | Application of cinnamon bark in the preparation of drugs for the prevention and treatment of largemouth bass viruses |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1897958A (en) * | 2003-12-24 | 2007-01-17 | 特拉维夫大学拉玛特有限公司 | Antiviral preparations obtained from a natural cinnamon extract |
| CN101460066A (en) * | 2006-03-23 | 2009-06-17 | 草药科学新加坡私人有限公司 | Extracts and methods comprising cinnamon species |
| CN106397624A (en) * | 2016-11-03 | 2017-02-15 | 宜春学院 | Aqueous extraction method of cinnamon polysaccharides |
| CN106606539A (en) * | 2016-12-16 | 2017-05-03 | 昆药集团股份有限公司 | Application of cinnamon polyphenol composition |
-
2017
- 2017-03-14 CN CN201710148704.7A patent/CN106957826B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1897958A (en) * | 2003-12-24 | 2007-01-17 | 特拉维夫大学拉玛特有限公司 | Antiviral preparations obtained from a natural cinnamon extract |
| CN101460066A (en) * | 2006-03-23 | 2009-06-17 | 草药科学新加坡私人有限公司 | Extracts and methods comprising cinnamon species |
| CN106397624A (en) * | 2016-11-03 | 2017-02-15 | 宜春学院 | Aqueous extraction method of cinnamon polysaccharides |
| CN106606539A (en) * | 2016-12-16 | 2017-05-03 | 昆药集团股份有限公司 | Application of cinnamon polyphenol composition |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112294868A (en) * | 2019-07-31 | 2021-02-02 | 昆明扬添生物科技有限公司 | Medicine for virus inactivation, sanitation disinfection and generation of immunity activation |
| CN112294868B (en) * | 2019-07-31 | 2023-11-21 | 昆明扬添生物科技有限公司 | Medicine for inactivating virus, sterilizing and activating immunity of organism |
| CN118593562A (en) * | 2024-05-21 | 2024-09-06 | 西北农林科技大学深圳研究院 | Application of cinnamon bark in the preparation of drugs for the prevention and treatment of largemouth bass viruses |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106957826B (en) | 2020-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112791179B (en) | Combined vaccine for preventing hand-foot-and-mouth disease and preparation method and application thereof | |
| CN112717128A (en) | Combined vaccine for preventing hand-foot-and-mouth disease and preparation method and application thereof | |
| CN116615234B (en) | A combined vaccine for the prevention of hand-foot-mouth disease, its preparation method and application | |
| CN104250637B (en) | One plant of bird flu H9N2 subtype virus strain and its application | |
| CN105441393B (en) | Very virulent infectious bursal disease virus DF-1 cell adapted strain and its application | |
| CN104928259A (en) | H9 subtype of avian influenza virus inactivating vaccine and preparation method thereof | |
| CN103937753B (en) | H9N2 subtype avian influenza virus strain and inactivated vaccine thereof and application | |
| CN112891525A (en) | Application of mycoplasma capricolum subspecies of capricolum in preparing vaccine for contagious pleuropneumonia of capricolum | |
| CN121015620A (en) | Application of domoic acid in the preparation of largemouth bass virus inhibitor | |
| CN103146654B (en) | Artificially weakened infectious bronchitis virus and application thereof | |
| CN104164410A (en) | Newcastle disease virus strain and application thereof in preparation of Newcastle disease vaccine | |
| CN116983400B (en) | Influenza attenuated live vaccine and application thereof | |
| CN113181229A (en) | Application of cabbage type rape-isatis tinctoria G monomer addition system in inhibiting novel coronavirus SARS-CoV-2 | |
| CN106957826B (en) | Virus inactivating agent and application thereof | |
| CN102805863B (en) | Preparation method of novel bunyavirus purification inactivated vaccine by culturing human diploid cell | |
| JP5713484B2 (en) | Composition for prevention and / or treatment of viral infections comprising plant extract, preventive and / or therapeutic agent for viral infections comprising these as active ingredients, and inhibitor of viral adsorption to cells | |
| CN101543627A (en) | Traditional Chinese medicine composition of compound immunoglobulin for treating respiratory diseases of poultry | |
| CN105039270B (en) | H9N2 subtype avian influenza acclimatization to cold attenuated strains and its application | |
| CN102994652A (en) | Method for detecting newcastle disease virus nucleic acid by RT-PCR | |
| CN102533673A (en) | Chicken infectious bursal disease very virulent cell adapted strain and application thereof | |
| CN101717398B (en) | Sophocarpine-series derivative as well as preparation method and purposes thereof | |
| CN101450207A (en) | Human influenza-poultry influenza combined vaccine and preparation method thereof | |
| CN104758340B (en) | Coffee mesitoyl quinine acid extract and its preparation method and application in a kind of folium lonicerae | |
| CN106166151A (en) | Indolal application in the medicine of resisiting influenza virus and the diseases associated with inflammation of preparation treatment influenza virus mediation | |
| CN115137762B (en) | Cyclocarya paliurus extract and application thereof in preparation of anti-coronavirus drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |